These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 22627303)

  • 1. Cost-benefit analysis of the tsutsugamushi disease prevention program in South Korea.
    Kim J; Lee E; Rhee HC
    Jpn J Infect Dis; 2012; 65(3):222-7. PubMed ID: 22627303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using cost-effectiveness/cost-benefit analysis to allocate health resources: a level playing field for prevention?
    Phillips KA; Hotlgrave DR
    Am J Prev Med; 1997; 13(1):18-25. PubMed ID: 9037338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medicaid-based child restraint system disbursement and education and the vaccines for children program: comparative cost-effectiveness.
    Goldstein JA; Winston FK; Kallan MJ; Branas CC; Schwartz JS
    Ambul Pediatr; 2008; 8(1):58-65. PubMed ID: 18191783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-benefit analysis of a prenatal preventive programme against congenital syphilis.
    Stray-Pedersen B
    NIPH Ann; 1980 May; 3(1):57-66. PubMed ID: 6779243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
    Kang HY; Ko SK; Liew D
    Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV prevention costs and program scale: data from the PANCEA project in five low and middle-income countries.
    Marseille E; Dandona L; Marshall N; Gaist P; Bautista-Arredondo S; Rollins B; Bertozzi SM; Coovadia J; Saba J; Lioznov D; Du Plessis JA; Krupitsky E; Stanley N; Over M; Peryshkina A; Kumar SG; Muyingo S; Pitter C; Lundberg M; Kahn JG
    BMC Health Serv Res; 2007 Jul; 7():108. PubMed ID: 17626616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Cost-Benefit Analysis of a State-Funded Healthy Homes Program for Residents With Asthma: Findings From the New York State Healthy Neighborhoods Program.
    Gomez M; Reddy AL; Dixon SL; Wilson J; Jacobs DE
    J Public Health Manag Pract; 2017; 23(2):229-238. PubMed ID: 28121775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Economic evaluation of public health interventions].
    García-Altés A; Navas E; Soriano MJ
    Gac Sanit; 2011 Jun; 25 Suppl 1():25-31. PubMed ID: 22055548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current situation of scrub typhus in South Korea from 2001-2013.
    Lee HW; Cho PY; Moon SU; Na BK; Kang YJ; Sohn Y; Youn SK; Hong Y; Kim TS
    Parasit Vectors; 2015 Apr; 8():238. PubMed ID: 25928653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Valuing prevention: discounting health benefits and costs in New Zealand.
    Milne R
    N Z Med J; 2005 May; 118(1214):U1443. PubMed ID: 15886738
    [No Abstract]   [Full Text] [Related]  

  • 11. [Economic evaluation as a component in the evaluation of a prevention program].
    Rydlewska-Liszkowska I
    Med Pr; 2004; 55(6):469-75. PubMed ID: 15887515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atherosclerotic cardiovascular diseases in Belgium: a cost-of-illness analysis.
    Vlayen J; De Backer G; Peers J; Moldenaers I; Debruyne H; Simoens S
    Cardiovasc Drugs Ther; 2008 Dec; 22(6):487-94. PubMed ID: 18792772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The value of a carotid duplex surveillance program for stroke prevention.
    Cull DL; Cole T; Miller B; Johnson B; Rawlinson D; Walker E; Taylor SM
    Ann Vasc Surg; 2011 Oct; 25(7):887-94. PubMed ID: 21835588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic analysis of measles elimination program in the Republic of Korea, 2001: a cost benefit analysis study.
    Bae GR; Choe YJ; Go UY; Kim YI; Lee JK
    Vaccine; 2013 May; 31(24):2661-6. PubMed ID: 23602654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cost-benefit model of the Rwanda family planning program].
    Rwanda. Office National de la Population ONAPO
    Imbonezamuryango; 1991 Aug; (21):25-37. PubMed ID: 12317097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of economic evidence in coverage decision-making in South Korea.
    Bae EY; Kim HJ; Lee HJ; Jang J; Lee SM; Jung Y; Yoon N; Kim TK; Kim K; Yang BM
    PLoS One; 2018; 13(10):e0206121. PubMed ID: 30356251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost and clinical implications of diabetes prevention in an Australian setting: a long-term modeling analysis.
    Palmer AJ; Tucker DM
    Prim Care Diabetes; 2012 Jul; 6(2):109-21. PubMed ID: 22153888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A cost-effectiveness analysis of a proposed national falls prevention program.
    Wu S; Keeler EB; Rubenstein LZ; Maglione MA; Shekelle PG
    Clin Geriatr Med; 2010 Nov; 26(4):751-66. PubMed ID: 20934620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic analysis of a school-based obesity prevention program.
    Wang LY; Yang Q; Lowry R; Wechsler H
    Obes Res; 2003 Nov; 11(11):1313-24. PubMed ID: 14627751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-benefit analysis of in-hospital influenza vaccination of postpartum women.
    Ding Y; Zangwill KM; Hay JW; Allred NJ; Yeh SH
    Obstet Gynecol; 2012 Feb; 119(2 Pt 1):306-14. PubMed ID: 22270282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.